Table 6.
Best overall responses
| Response, n (%) | 120 mg AP (n = 6) |
200 mg AP (n = 7) |
250 mg AP (n = 8) |
300 mg AP (n = 5) |
Total (N = 26) |
|---|---|---|---|---|---|
| CR | 0 | 0 | 1 (12.5) | 0 | 1 (3.8) |
| CRp | 0 | 0 | 0 | 0 | 0 |
| CRi/MLFS | 0 | 0 | 0 | 1 (20.0) | 1 (3.8) |
| Partial response | 0 | 1 (14.3) | 1 (12.5) | 0 | 2 (7.7) |
| HI/SD | 2 (33.3) | 2 (28.6) | 2 (25.0) | 1 (20.0) | 7 (26.9) |
| PD | 4 (66.7) | 2 (28.6) | 2 (25.0) | 2 (40.0) | 10 (38.5) |
| Not evaluable/missing | 0 | 2 (28.6) | 2 (25.0) | 1 (20.0) | 5 (19.2) |
CR complete remission, CRi complete remission with incomplete recovery of peripheral counts, CRp complete remission without platelet recovery, HI hematologic improvement, MLFS morphological leukemia-free state, PD progressive disease, SD stable disease